Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07267065 · ClinicalTrials.gov registry record · Phase 1
AAV2-hAADC for Parkinson's Disease (PDCS-01)
A Phase 1 study, sponsored by Krzysztof Bankiewicz.
- Not yet
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT07267065: Clinical Trial Phase 1 study, sponsored by Krzysztof Bankiewicz.
NCT07267065 is a Phase 1 study that has not yet begun recruiting, run by Krzysztof Bankiewicz. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07267065, a Phase 1 study, has not yet begun recruiting, sponsored by Krzysztof Bankiewicz.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is looking at whether a gene therapy called AAV2-hAADC is safe and may help people with Parkinson's Disease. AAV2-hAADC is intended to increase the levels of dopamine in your brain. It contains a virus called adeno-associated virus 2 (AAV2) that has been modified to carry the genetic code for an enzyme called Aromatic L-Amino Acid Decarboxylase, or AADC for short. In this study, AAV2-hAADC is delivered to two parts of the brain called the putamen and the caudate. Increasing the amount of AADC gene in these parts of the brain converts more levodopa into dopamine, the chemical that is lacking in PD.
Primary Outcome
Assessment of AEs or SAEs and their relationship to the study procedure and study drug (graded as definite, probable, possible, unlikely, or unrelated).
Interventions
- DRUG AAV2-hAADC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
What is known before NCT07267065 opens enrollment
NCT07267065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which AAV2-hAADC is the first listed.
NCT07267065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07267065 about?
NCT07267065 is a clinical study titled "AAV2-hAADC for Parkinson's Disease (PDCS-01)". This study is looking at whether a gene therapy called AAV2-hAADC is safe and may help people with Parkinson's Disease. AAV2-hAADC is intended to increase the levels of dopamine in your brain. It contains a virus called adeno-associated virus 2 (AAV2) that has been modified to carry the genetic cod...
What is the current status of trial NCT07267065?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2026-02-01. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07267065?
The interventions under investigation include: AAV2-hAADC (DRUG).
Who is sponsoring clinical trial NCT07267065?
This trial is sponsored by Krzysztof Bankiewicz, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07267065's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI